← Back to Search
Pharmacokinetics Of Pegylated Liposomal Doxorubicin
A. Gabizon, H. Shmeeda, Y. Barenholz
Published 2003 · Medicine
Download PDFAnalyze on Scholarcy
Pegylated liposomal doxorubicin (doxorubicin HCl liposome injection; Doxil® or Caelyx®) is a liposomal formulation of doxorubicin, reducing uptake by the reticulo-endothelial system due to the attachment of polyethylene glycol polymers to a lipid anchor and stably retaining drug as a result of liposomal entrapment via an ammonium sulfate chemical gradient. These features result in a pharmacokinetic profile characterised by an extended circulation time and a reduced volume of distribution, thereby promoting tumour uptake.Preclinical studies demonstrated one- or two-phase plasma concentration-time profiles. Most of the drug is cleared with an elimination half-life of 20–30 hours. The volume of distribution is close to the blood volume, and the area under the concentration-time curve (AUC) is increased at least 60-fold compared with free doxorubicin. Studies of tissue distribution indicated preferential accumulation into various implanted tumours and human tumour xenografts, with an enhancement of drug concentrations in the tumour when compared with free drug.Clinical studies of pegylated liposomal doxorubicin in humans have included patients with AIDS-related Kaposi’s sarcoma (ARKS) and with a variety of solid tumours, including ovarian, breast and prostate carcinomas. The pharmacokinetic profile in humans at doses between 10 and 80 mg/m2 is similar to that in animals, with one or two distribution phases: an initial phase with a half-life of 1–3 hours and a second phase with a half-life of 30–90 hours. The AUC after a dose of 50 mg/m2 is approximately 300-fold greater than that with free drug. Clearance and volume of distribution are drastically reduced (at least 250-fold and 60-fold, respectively). Preliminary observations indicate that utilising the distinct pharmacokinetic parameters of pegylated liposomal doxorubicin in dose scheduling is an attractive possibility.In agreement with the preclinical findings, the ability of pegylated liposomes to extravasate through the leaky vasculature of tumours, as well as their extended circulation time, results in enhanced delivery of liposomal drug and/or radiotracers to the tumour site in cancer patients. There is evidence of selective tumour uptake in malignant effusions, ARKS skin lesions and a variety of solid tumours.The toxicity profile of pegylated liposomal doxorubicin is characterised by dose-limiting mucosal and cutaneous toxicities, mild myelosuppression, decreased cardiotoxicity compared with free doxorubicin and minimal alopecia. The mucocutaneous toxicities are dose-limiting per injection; however, the reduced cardiotoxicity allows a larger cumulative dose than that acceptable for free doxorubicin.Thus, pegylated liposomal doxorubicin represents a new class of chemotherapy delivery system that may significantly improve the therapeutic index of doxorubicin.
This paper references
Pharmacokinetics of stealth versus conventional liposomes: effect of dose.
T. Allen (1991)
Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)
M. S. Newman (1994)
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Z. Symon (1999)
Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
A. Hubert (2000)
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
D. Lasic (1995)
Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes
A. Gabizon (1993)
Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes.
E. Bolotin (1994)
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.
F. Yuan (1994)
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
P. Gill (1995)
DRV Liposomal Bupivacaine: Preparation, Characterization, and In Vivo Evaluation in Mice
G. J. Grant (2004)
Phase I and pharmacokinetic study of a stable, polyethylene‐glycolated liposomal doxorubicin in patients with solid tumors
R. Hong (2001)
Openings between defective endothelial cells explain tumor vessel leakiness.
H. Hashizume (2000)
Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models.
S. Bandak (1999)
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin
T. Safra (2001)
High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy.
M. Koukourakis (2000)
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma
M. Amantea (1997)
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
Gelation of liposome interior A novel method for drug encapsulation
D. Lasic (1992)
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
B. Uziely (1995)
Significant Increase in Antitumor Potency of Doxorubicin Hc1 by its Encapsulation in Pegylated Liposomes
G. Colbern (1999)
Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models
A. Gabizon (2002)
Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
J. Vaage (1994)
Phase I study of liposomal vincristine.
K. Gelmon (1999)
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
A. Gabizon (1995)
Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
T. Siegal (1995)
Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs
A. Gabizon (2004)
Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
O. Lyass (2001)
Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
P. Working (1999)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.
G. Haran (1993)
Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles.
P. Cullis (1997)
LIPOSOMAL ANTHRACYCLINE CHEMOTHERAPY IN THE TREATMENT OF AIDS : RELATED KAPOSI'S SARCOMA
D. W. Northfelt (1997)
In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.
A. Horowitz (1992)
A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas.
A. Garcia (1998)
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer.
A. Hamilton (2002)
Pegylated Liposomal Doxorubicin: Scientific Rationale and Preclinical Pharmacology
F. J. Martin (1997)
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
D. Northfelt (1996)
Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
D. Vail (1998)
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.
A. Gabizon (1997)
Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer.
M. Koukourakis (1999)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.
D. Papahadjopoulos (1991)
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
R. Hong (1999)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
K. Harrington (2001)
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.
A. Gabizon (1994)
Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma.
J. Vaage (1997)
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)
Liposome application: problems and prospects
Y. Barenholz (2001)
Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
A. Gabizon (1992)
Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice
M. Bally (2004)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
F. Yuan (1995)
Development of liposomal anthracyclines: from basics to clinical applications.
A. Gabizon (1998)
Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
S. Toma (2000)
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
A. Gabizon (2001)
Uptake of small liposomes by non-reticuloendothelial tissues.
K. J. Hwang (1987)
TARGETING OF DRUGS: IMPLICATIONS IN MEDICINE
G. Gregoriadis (1981)
Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.
A. Gabizon (1996)
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.
S. Huang (1992)
European Organization for Research and Treatment of Cancer.
H. Fukuda (2000)
Sterically stabilized liposomes.
M. Woodle (1992)
Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Dayan Ad (1996)
Long Circulating Liposomes: Old Drugs, New Therapeutics
M. Woodle (1998)
Liposomal encapsulated anthracyclines: new therapeutic horizons
F. Muggia (2001)
Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study.
N. Marina (2002)
Initial Clinical Evaluation of Pegylated-Liposomal Doxorubicin in Solid Tumors
A. Gabizon (1998)
The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs.
R. Juliano (1975)
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.
G. Poste (1982)
Pharmacokinetics of anticancer agents in humans
M. Ames (1983)
Liposomes: preparation, characterization, and preservation.
D. Lichtenberg (1988)
High intratumoural accumulation of stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and in metastatic brain tumours
M. Koukourakis (2000)
Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals
A. Gabizon (1997)
This paper is referenced by
MR-HIFU mediated local drug delivery using temperature-sensitive liposomes
de M Mariska Smet (2013)
Steroidal Nanodrugs Based on Pegylated Nanoliposomes Remote Loaded with Amphipathic Weak Acids Steroid Prodrugs as Anti-Inflammatory Agents
Keren Turjeman (2016)
Mathematical modelling of drug delivery to solid tumour
Wenbo Zhan (2014)
Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.
Mohamad Hadla (2016)
Use of liposomal doxorubicin–cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study
B. Linot (2014)
Liposomes as nanocarriers of lipid-conjugated antitumor drugs melphalan and methotrexate
E. Vodovozova (2008)
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
Jianqin Lu (2018)
Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?
João Conde (2013)
Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance
Xiaohui Wei (2018)
Complete remission of a case of classical Kaposi's sarcoma with liposomal doxorubicin and radiotherapy
G. M. Ezquerra (2006)
Nanotechnology for delivery of drugs to the brain for epilepsy
Margaret F Bennewitz (2011)
Clinical applications of nanomedicine in cancer therapy.
M. Norouzi (2019)
Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
Yaelle Bavli (2019)
Lipid-Based Tumor-targeted Systems
Yaxi Li (2020)
A Versatile Nanotheranostic Agent for Efficient Dual-Mode Imaging Guided Synergistic Chemo-Thermal Tumor Therapy
X. Cai (2015)
Nanoparticle Therapies for Wounds and Ulcer Healing
Gardin Chiara (2013)
A novel two-step mild hyperthermia for advanced liposomal chemotherapy.
L. Li (2014)
Toxicological status of nanoparticles: What we know and what we don't know.
Wided N Missaoui (2018)
Paramagnetic liposomes for molecular MRI and MRI‐guided drug delivery
S. Langereis (2013)
Chlorin p6-Based Water-Soluble Amino Acid Derivatives as Potent Photosensitizers for Photodynamic Therapy.
Zhi Meng (2016)
Factors influencing the surface modification of mesenchymal stem cells with fluorescein-pegylated lipids.
Yoshimasa Takafuji (2013)
Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges
Prameela Kandra (2015)
DRUG DELIVERY NANOCARRIERS TO CROSS OF THE BLOOD-BRAIN BARRIER
C. Palazzo (2016)
A minimal physiologically based pharmacokinetic model that predicts anti‐PEG IgG‐mediated clearance of PEGylated drugs in human and mouse
M. McSweeney (2018)
Preparation and Characterization of Baicalein-Loaded Nanoliposomes for Antitumor Therapy
K. Li (2016)
QUANTIFICATION OF FACTORS GOVERNING DRUG RELEASE KINETICS FROM NANOPARTICLES: A COMBINED EXPERIMENTAL AND MECHANISTIC MODELING APPROACH
Kyle D. Fugit (2014)
Zoledronic acid: an unending tale for an antiresorptive agent
M. Caraglia (2010)
Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence.
H. Chen (2013)
Biochemical Pathways in Cancer
E. Breuer (2012)
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Eunus S Ali (2020)
Targeting nanoparticles to cancer.
M. Wang (2010)
Doxorubicin-encapsulated Albumin liposomes with acoustic triggering for cancer treatment
Afifa Farooq (2019)See more